Sarcoma

Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia

Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia

By

Researchers reviewed cancer incidence in patients with Diamond-Blackfan anemia.

The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients

The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients

[Cancer Management and Research] Researchers sought to determine the effect of intravenous hydration on plasma methotrexate clearance on pediatric oncology patients receiving HD-MTX for ALL, NHL, or osteosarcoma.

Prognostic Factors for Survival Among Patients With Primary Bone Sarcomas of Small Bones

Prognostic Factors for Survival Among Patients With Primary Bone Sarcomas of Small Bones

[Cancer Management and Research] The prognostic values of overall survival and cancer-specific survival for bone sarcomas of the hands or feet were assessed using Cox proportional hazards regression model with univariate and multivariate analyses.

Elderly Patients Are Underrepresented in Trials For Soft Tissue Sarcoma

Elderly Patients Are Underrepresented in Trials For Soft Tissue Sarcoma

By

With median age of participants in clinical trials for soft-tissue sarcoma younger than most patients who develop the disease, these researchers sought to determine the prevalence of including persons older than 65 in clinical trials and the efficacy of first-line chemotherapy for STS in older patients.

Developments in the Management of Advanced Soft-tissue Sarcoma - Olaratumab in Context

Developments in the Management of Advanced Soft-tissue Sarcoma - Olaratumab in Context

[OncoTargets and Therapy] This review examines the rationale of olaratumab in the treatment of advanced soft-tissue sarcomas and its emerging role in clinical practice.

Exercise May Mitigate Cardiotoxicity Associated With Doxorubicin Treatment

Exercise May Mitigate Cardiotoxicity Associated With Doxorubicin Treatment

Researchers injected Ewing sarcoma cells into mice to determine the effects of exercise on doxorubicin efficacy and treatment-related cardiotoxicity.

Vitamin D Supplementation is Recommended for Use in Young Patients With Sarcoma

Vitamin D Supplementation is Recommended for Use in Young Patients With Sarcoma

By

Just over half of patients in a standard therapy group had normal bone mineral density after a mean follow-up of 6 years; this contrasted with 93% of patients in a vitamin D supplementation group.

Progression-Free, Overall Survival in Liposarcoma Improved With Eribulin vs Dacarbazine

Progression-Free, Overall Survival in Liposarcoma Improved With Eribulin vs Dacarbazine

By

Comparison study shows significantly improved overall survival and progression-free survival in patients with advanced LPS treated with eribulin vs dacarbazine.

Autologous T-Cell Therapy Promising in Advanced Sarcoma

Autologous T-Cell Therapy Promising in Advanced Sarcoma

By

After lymphodepletion in patients with advanced HER2+ sarcoma, T cells expanded in 5 of 6 patients who received infusions of HER2-CAR T cells.

Regorafenib Improves Quality-adjusted Survival in Sarcoma

Regorafenib Improves Quality-adjusted Survival in Sarcoma

By

In patients with soft tissue sarcoma pretreated with doxorubicin, treatment with regorafenib significantly reduced the risk of progression symptoms or toxicity.

Regional Chemotherapy Technique May Help Prevent Amputations

Regional Chemotherapy Technique May Help Prevent Amputations

By

Researchers indicate that it may be possible lower amputation rates by nearly 80% in patients with extremity sarcomas.

Propranolol May Be Repurposed to Treat Angiosarcoma

Propranolol May Be Repurposed to Treat Angiosarcoma

By

A drug currently used for hypertension may be effective for patients with soft tissue sarcoma, based on the finding of researchers in Europe.

Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas

By

In a phase 1 clinical trial, the combination produces a significant and long-lasting response in patients with advanced disease including metastases to the peritoneum and lung.

Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma

By

The US FDA granted accelerated approval to olaratumab (Lartruvo) in combination with doxorubicin for the treatment of certain patients with soft tissue sarcoma.

Experimental Targeted Therapy Succeeds in Rare Pediatric Cancer

By

The experimental treatment LOXO-101 led to remarkable improvement for a 20-month-old girl whose rare pediatric cancer did not respond to surgery or chemotherapy.

New Therapy Holds Promise for Patients With Ewing Sarcoma

By

Two new compounds suppress tumor growth in cell culture and mouse xenograft models of Ewing sarcoma, a rare pediatric cancer. These 2 compounds are similar to mithramycin, also known as picamycin, a drug no longer manufactured due to its toxicity.

Studies Demonstrate Clinical Advantages of Proton Therapy

Studies Demonstrate Clinical Advantages of Proton Therapy

By

The search for evidence to support the growing use of proton therapy for more cancers continues to uncover valuable findings. New data from clinical trials demonstrate the potential advantages of proton therapy over conventional radiation for pancreatic cancer, late-stage non-small cell lung cancer, chordoma, and chondrosarcoma.

Gene Signature May Predict Survival Outcomes for Some Children With Rhabdomyosarcoma

By

Among children with intermediate-risk rhabdomyosarcoma that is negative for a fusion gene, those who had a high score of the specific gene signature MG5 had poorer survival outcomes compared with those who had a low score of MG5.

FDA Approves Trabectedin for Metastatic or Unresectable Soft Tissue Sarcoma

FDA Approves Trabectedin for Metastatic or Unresectable Soft Tissue Sarcoma

By

The FDA has approved trabectedin (Yondelis) for treatment of unresectable or metastatic soft tissue sarcoma.

Trabectedin Confers Long-Term Efficacy in Soft Tissue Sarcoma

By

A large prospective postcommercialization study in patients with advanced STS in Europe confirmed the long-term anticancer activity of trabectedin (Yondelis) in different subtypes of sarcoma.

Aldoxorubicin may be safe, effective for advanced soft-tissue sarcoma

Aldoxorubicin may be safe, effective for advanced soft-tissue sarcoma

Single-agent aldoxorubicinshowed superior efficacy over doxorubicin and manageable adverse effects in advanced soft-tissue sarcoma.

Potential treatment option discovered for children with Ewing's sarcoma

By

Combining two anti-tumor agents appears to increase the sensitivity of cancer cells to these drugs and seems to lead to more effective Ewing's sarcoma treatment.

Endoscopic extraction of spinal tumor achieves diagnosis and successful treatment

By

The first reported case of endoscopic spinal tumor extraction enabled accurate diagnosis and allowed for patient reporting of sensations and motor testing.

Survival from rare bone cancer remains low

By

Mesenchymal chondrosarcoma, which often affects young adults, is among the deadliest cancers.

Sarcoma patients' significant symptom burden negatively impacts quality of life

Sarcoma patients' significant symptom burden negatively impacts quality of life

Adult patients with sarcoma experience significant symptom burden, which has a strong negative impact on health-related quality of life.

Prolonged therapy with trabectedin recommended for soft-tissue sarcoma

By

Data from a phase 2 trial supports continuation of trabectedin for patients with advanced soft-tissue sarcoma (STS) who have not progressed after six courses of treatment.

Potential therapeutic strategy against a very aggressive children's bone cancer

By

Inhibiting the protein Sirtuin1 could play a part in fighting Ewing sarcoma, a common bone cancer in adolescents and children.

Advanced image guidance more precisely targets sarcomas, reduces long-term side effects

Advanced image guidance more precisely targets sarcomas, reduces long-term side effects

Image-guided radiotherapy can effectively treat soft tissue sarcomas in the extremities.

Single genetic abnormality important in Ewing sarcoma

Single genetic abnormality important in Ewing sarcoma

By

Better understanding of the two distinct processes at the heart of the genetic abnormality driving Ewing sarcoma development could lead to new, more effective therapies.

Experimental breast cancer drug holds promise in combination therapy for Ewing sarcoma

By

When Ewing sarcoma tumors in mice were treated with combination therapy that included drugs from a family of agents developed to fight breast cancer, the tumors disappeared in a majority of test cases.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs